Trade GlycoMimetics - GLYC CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0280 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
GlycoMimetics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 1.696 |
| Open* | 1.716 |
| 1-Year Change* | -22.96% |
| Day's Range* | 1.526 - 1.716 |
| 52 wk Range | 1.11-4.16 |
| Average Volume (10 days) | 84.80K |
| Average Volume (3 months) | 2.51M |
| Market Cap | 96.59M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 64.39M |
| Revenue | N/A |
| EPS | -0.64 |
| Dividend (Yield %) | N/A |
| Beta | 2.08 |
| Next Earnings Date | Mar 27, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | 1.6960 | 0.0900 | 5.60% | 1.6060 | 1.7160 | 1.5960 |
| Nov 30, 2023 | 1.6360 | 0.1400 | 9.36% | 1.4960 | 1.6460 | 1.4860 |
| Nov 29, 2023 | 1.4960 | 0.0000 | 0.00% | 1.4960 | 1.5460 | 1.4960 |
| Nov 28, 2023 | 1.5160 | 0.0300 | 2.02% | 1.4860 | 1.5160 | 1.4460 |
| Nov 27, 2023 | 1.5160 | -0.0700 | -4.41% | 1.5860 | 1.5860 | 1.5160 |
| Nov 24, 2023 | 1.5260 | 0.0100 | 0.66% | 1.5160 | 1.5860 | 1.4660 |
| Nov 22, 2023 | 1.4760 | 0.0200 | 1.37% | 1.4560 | 1.5160 | 1.3760 |
| Nov 21, 2023 | 1.4660 | 0.0200 | 1.38% | 1.4460 | 1.4960 | 1.4460 |
| Nov 20, 2023 | 1.5060 | 0.0600 | 4.15% | 1.4460 | 1.5460 | 1.4460 |
| Nov 17, 2023 | 1.3960 | 0.1300 | 10.27% | 1.2660 | 1.4360 | 1.2460 |
| Nov 16, 2023 | 1.3260 | 0.0000 | 0.00% | 1.3260 | 1.3860 | 1.2560 |
| Nov 15, 2023 | 1.3460 | 0.0000 | 0.00% | 1.3460 | 1.4360 | 1.2960 |
| Nov 14, 2023 | 1.3260 | 0.0400 | 3.11% | 1.2860 | 1.3560 | 1.2360 |
| Nov 13, 2023 | 1.2960 | 0.1000 | 8.36% | 1.1960 | 1.3160 | 1.1660 |
| Nov 10, 2023 | 1.1760 | -0.0400 | -3.29% | 1.2160 | 1.2160 | 1.1660 |
| Nov 9, 2023 | 1.1860 | -0.1200 | -9.19% | 1.3060 | 1.3360 | 1.1560 |
| Nov 8, 2023 | 1.3160 | -0.0200 | -1.50% | 1.3360 | 1.3560 | 1.2860 |
| Nov 7, 2023 | 1.3360 | 0.0400 | 3.09% | 1.2960 | 1.4060 | 1.2760 |
| Nov 6, 2023 | 1.3260 | 0.0200 | 1.53% | 1.3060 | 1.3360 | 1.2960 |
| Nov 3, 2023 | 1.3360 | 0.0100 | 0.75% | 1.3260 | 1.3460 | 1.2760 |
GlycoMimetics Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, March 27, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q4 2023 GlycoMimetics Inc Earnings Release Q4 2023 GlycoMimetics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0.075 | 1.15977 | 10.1629 | 0 | 0 |
| Revenue | 0.075 | 1.15977 | 10.1629 | 0 | 0 |
| Total Operating Expense | 47.4783 | 64.607 | 61.6723 | 61.3893 | 51.5048 |
| Selling/General/Admin. Expenses, Total | 19.0874 | 17.1154 | 16.7431 | 14.36 | 11.413 |
| Research & Development | 28.3909 | 47.4916 | 44.9292 | 47.0293 | 40.0918 |
| Operating Income | -47.4033 | -63.4472 | -51.5094 | -61.3893 | -51.5048 |
| Interest Income (Expense), Net Non-Operating | 0.71452 | 0.01977 | 0.48249 | 3.49739 | 3.23119 |
| Net Income Before Taxes | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Net Income After Taxes | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Net Income Before Extra. Items | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Net Income | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Income Available to Common Excl. Extra. Items | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Income Available to Common Incl. Extra. Items | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Diluted Net Income | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Diluted Weighted Average Shares | 52.5312 | 51.4532 | 45.7211 | 43.2548 | 41.0446 |
| Diluted EPS Excluding Extraordinary Items | -0.88878 | -1.23272 | -1.11605 | -1.33839 | -1.17613 |
| Diluted Normalized EPS | -0.88878 | -1.23272 | -1.11605 | -1.33839 | -1.17613 |
| Total Extraordinary Items |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0.075 |
| Revenue | 0 | 0 | 0 | 0.075 | |
| Total Operating Expense | 8.92995 | 10.941 | 10.6226 | 8.76744 | 13.4282 |
| Selling/General/Admin. Expenses, Total | 4.85724 | 5.52231 | 4.7318 | 3.84458 | 5.45488 |
| Research & Development | 4.07271 | 5.41871 | 5.89082 | 4.92286 | 7.97328 |
| Operating Income | -8.92995 | -10.941 | -10.6226 | -8.76744 | -13.3532 |
| Interest Income (Expense), Net Non-Operating | 0.67103 | 0.58167 | 0.37827 | 0.2436 | 0.08559 |
| Net Income Before Taxes | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Net Income After Taxes | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Net Income Before Extra. Items | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Net Income | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Income Available to Common Excl. Extra. Items | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Income Available to Common Incl. Extra. Items | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Diluted Net Income | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Diluted Weighted Average Shares | 64.2762 | 60.3501 | 52.962 | 52.4239 | 52.4073 |
| Diluted EPS Excluding Extraordinary Items | -0.12849 | -0.17165 | -0.19343 | -0.16259 | -0.25316 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.12849 | -0.17165 | -0.19343 | -0.16259 | -0.25316 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 50.7147 | 90.7887 | 138.273 | 162.528 | 212.269 |
| Cash and Short Term Investments | 47.8706 | 90.2549 | 137.035 | 158.201 | 209.918 |
| Cash & Equivalents | 47.8706 | 90.2549 | 137.035 | 158.201 | 209.918 |
| Short Term Investments | |||||
| Total Receivables, Net | 0.14402 | 0.00135 | 0.00215 | 0.18595 | 0.41312 |
| Prepaid Expenses | 2.70007 | 0.53246 | 1.23618 | 4.14037 | 1.9384 |
| Total Assets | 51.8106 | 94.3466 | 142.832 | 167.97 | 214.839 |
| Property/Plant/Equipment, Total - Net | 0.99356 | 1.94503 | 2.9459 | 3.82899 | 0.95723 |
| Property/Plant/Equipment, Total - Gross | 3.38018 | 4.26792 | 5.0782 | 5.69053 | 2.54087 |
| Accumulated Depreciation, Total | -2.38662 | -2.3229 | -2.1323 | -1.86155 | -1.58364 |
| Other Long Term Assets, Total | 0.10232 | 1.61293 | 1.61293 | 1.61293 | 1.61293 |
| Total Current Liabilities | 8.88075 | 11.8244 | 12.4284 | 10.9506 | 8.76315 |
| Accounts Payable | 0.97019 | 2.10762 | 2.08994 | 1.43566 | 2.66358 |
| Accrued Expenses | 7.91056 | 9.71678 | 10.3384 | 9.51492 | 6.0008 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.09877 | ||||
| Total Liabilities | 8.88075 | 12.743 | 14.6127 | 13.7691 | 9.37478 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0 | 0.91861 | 2.18434 | 2.81852 | 0.61162 |
| Total Equity | 42.9298 | 81.6037 | 128.219 | 154.201 | 205.464 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
| Common Stock | 0.05438 | 0.05231 | 0.04902 | 0.04347 | 0.04316 |
| Additional Paid-In Capital | 462.461 | 454.448 | 437.64 | 412.6 | 405.972 |
| Retained Earnings (Accumulated Deficit) | -419.586 | -372.897 | -309.47 | -258.443 | -200.551 |
| Total Liabilities & Shareholders’ Equity | 51.8106 | 94.3466 | 142.832 | 167.97 | 214.839 |
| Total Common Shares Outstanding | 54.3778 | 52.3139 | 49.0176 | 43.4669 | 43.1608 |
| Total Preferred Shares Outstanding |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 52.0101 | 60.3688 | 68.0865 | 50.7147 | 53.8482 |
| Cash and Short Term Investments | 49.4076 | 58.0371 | 65.0023 | 47.8706 | 51.6248 |
| Cash & Equivalents | 49.4076 | 58.0371 | 65.0023 | 47.8706 | 51.6248 |
| Total Receivables, Net | 0.18895 | 0.21537 | 0.23411 | 0.14402 | 0.09033 |
| Prepaid Expenses | 2.4135 | 2.11639 | 2.85008 | 2.70007 | 2.13309 |
| Total Assets | 53.2007 | 61.8215 | 68.9217 | 51.8106 | 55.9614 |
| Property/Plant/Equipment, Total - Net | 1.08829 | 1.35036 | 0.7328 | 0.99356 | 1.25313 |
| Property/Plant/Equipment, Total - Gross | 3.59843 | 3.81775 | 3.16326 | 3.38018 | 3.59403 |
| Accumulated Depreciation, Total | -2.51014 | -2.46739 | -2.43045 | -2.38662 | -2.3409 |
| Other Long Term Assets, Total | 0.10232 | 0.10232 | 0.10232 | 0.10232 | 0.86012 |
| Total Current Liabilities | 6.39088 | 6.572 | 6.74021 | 8.88075 | 7.74825 |
| Accounts Payable | 0.32989 | 0.24149 | 0.48015 | 0.97019 | 0.85213 |
| Accrued Expenses | 6.061 | 6.33052 | 6.26006 | 7.91056 | 6.89613 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 6.65301 | 7.02078 | 6.74021 | 8.88075 | 7.84386 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.26213 | 0.44878 | 0 | 0.09561 | |
| Total Equity | 46.5477 | 54.8007 | 62.1814 | 42.9298 | 48.1176 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.06437 | 0.06431 | 0.06425 | 0.05438 | 0.05242 |
| Additional Paid-In Capital | 493.89 | 492.94 | 492.062 | 462.461 | 457.407 |
| Retained Earnings (Accumulated Deficit) | -447.407 | -438.204 | -429.945 | -419.586 | -409.341 |
| Total Liabilities & Shareholders’ Equity | 53.2007 | 61.8215 | 68.9217 | 51.8106 | 55.9614 |
| Total Common Shares Outstanding | 64.3688 | 64.3133 | 64.2452 | 54.3778 | 52.4239 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Cash From Operating Activities | -46.4575 | -57.4895 | -39.2419 | -51.9841 | -43.3311 |
| Cash From Operating Activities | 0.20715 | 0.2646 | 0.27075 | 0.27923 | 0.27512 |
| Non-Cash Items | 4.68609 | 6.8385 | 7.5826 | 6.83516 | 4.58727 |
| Cash Taxes Paid | |||||
| Changes in Working Capital | -4.66192 | -1.16519 | 3.93162 | -1.20662 | 0.08011 |
| Cash From Investing Activities | -0.08419 | -0.01494 | -0.06851 | -0.14493 | -0.12562 |
| Capital Expenditures | -0.08419 | -0.01494 | -0.06851 | -0.14493 | -0.12562 |
| Cash From Financing Activities | 4.15741 | 10.7243 | 18.144 | 0.41291 | 129.45 |
| Issuance (Retirement) of Stock, Net | 4.15741 | 10.7243 | 18.144 | 0.41291 | 129.45 |
| Net Change in Cash | -42.3843 | -46.7801 | -21.1664 | -51.7161 | 85.9929 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -10.3594 | -46.6888 | -36.4445 | -27.9206 | -14.653 |
| Cash From Operating Activities | -11.6069 | -46.4575 | -38.5459 | -29.9288 | -13.6981 |
| Cash From Operating Activities | 0.04384 | 0.20715 | 0.16143 | 0.11408 | 0.05931 |
| Non-Cash Items | 1.0893 | 4.68609 | 3.57304 | 2.45038 | 1.27946 |
| Changes in Working Capital | -2.38065 | -4.66192 | -5.83594 | -4.57266 | -0.38387 |
| Cash From Investing Activities | -0.0022 | -0.08419 | -0.08419 | -0.08171 | -0.04052 |
| Capital Expenditures | -0.0022 | -0.08419 | -0.08419 | -0.08171 | -0.04052 |
| Cash From Financing Activities | 28.7408 | 4.15741 | 0 | 0 | 0 |
| Issuance (Retirement) of Stock, Net | 28.7408 | 4.15741 | 0 | 0 | 0 |
| Net Change in Cash | 17.1317 | -42.3843 | -38.6301 | -30.0105 | -13.7387 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| BVF Partners L.P. | Hedge Fund | 14.8396 | 9544262 | 0 | 2023-06-30 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 13.3544 | 8589064 | 0 | 2023-06-30 | MED |
| New Enterprise Associates (NEA) | Venture Capital | 7.4078 | 4764440 | 0 | 2023-06-30 | LOW |
| Octagon Capital Advisors LP | Hedge Fund | 4.6644 | 3000000 | 0 | 2023-06-30 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.5985 | 2314405 | -146428 | 2023-06-30 | LOW |
| AXA Investment Managers UK Ltd. | Investment Advisor/Hedge Fund | 2.5367 | 1631509 | 22448 | 2023-06-30 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 1.7875 | 1149656 | -251997 | 2023-06-30 | MED |
| Goldman Sachs & Company, Inc. | Research Firm | 1.2186 | 783731 | -118160 | 2023-06-30 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.1909 | 765953 | 124925 | 2023-06-30 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.0135 | 651814 | -313255 | 2023-06-30 | HIGH |
| King (Rachel K) | Individual Investor | 0.9409 | 605139 | 6667 | 2023-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7405 | 476240 | 70905 | 2023-06-30 | LOW |
| Rock (Edwin) | Individual Investor | 0.5837 | 375403 | 65403 | 2023-09-22 | LOW |
| Magnani (John L) | Individual Investor | 0.5365 | 345048 | 45045 | 2022-11-11 | |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2904 | 186765 | 0 | 2023-06-30 | LOW |
| Rath (Chinmaya) | Individual Investor | 0.2506 | 161178 | 161178 | 2023-03-23 | |
| Connor, Clark & Lunn Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.2428 | 156191 | -2810 | 2023-06-30 | MED |
| Marshall Wace LLP | Investment Advisor/Hedge Fund | 0.2214 | 142400 | -73899 | 2023-06-30 | HIGH |
| Johnson (Bruce S) | Individual Investor | 0.2161 | 138980 | 13500 | 2023-05-08 | LOW |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.2113 | 135900 | 25500 | 2023-06-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
GlycoMimetics Company profile
About GlycoMimetics Inc
GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of novel glycomimetic. Its drug candidates include Uproleselan, GMI-1359, Rivipansel, GMI-1687, and Galectin Antagonists. Its Uproleselan a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), a life-threatening hematologic cancer, and potentially other hematologic cancers. The GMI-1359 targets E-selectin and a chemokine receptor. Its Rivipansel is a glycomimetic drug candidate that act as , a pan-selectin antagonist for treatment of vaso-occlusive crisis. It has designed antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. Galectin Antagonists includes Galectin-3, which is a carbohydrate-binding protein.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, GlycoMimetics Inc revenues decreased 89% to $1.2M. Net loss increased 24% to $63.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research & Development Expenses increase of 8% to $45.3M (expense), Interest income decrease of 96% to $20K (income).
Equity composition
Common Stock, $0.001 Par, 100M Auth shares, 17,555,497 issd,. Insiders Owns approx. 10.08%.
| Industry: | Bio Therapeutic Drugs |
9708 Medical Center Drive
ROCKVILLE
MARYLAND 20850
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com